Compare LTC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTC | QURE |
|---|---|---|
| Founded | 1992 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | 248 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 663.4M |
| IPO Year | 1994 | 2013 |
| Metric | LTC | QURE |
|---|---|---|
| Price | $39.10 | $15.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $39.00 | ★ $45.42 |
| AVG Volume (30 Days) | 339.5K | ★ 4.7M |
| Earning Date | 05-27-2026 | 06-02-2026 |
| Dividend Yield | ★ 5.84% | N/A |
| EPS Growth | 23.53 | ★ 29.67 |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $262,854,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $126.14 |
| Revenue Next Year | $13.24 | $395.00 |
| P/E Ratio | $15.48 | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $31.70 | $7.76 |
| 52 Week High | $40.80 | $71.50 |
| Indicator | LTC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 43.09 |
| Support Level | $38.08 | $13.29 |
| Resistance Level | $40.43 | $16.62 |
| Average True Range (ATR) | 0.82 | 2.08 |
| MACD | -0.15 | 0.25 |
| Stochastic Oscillator | 44.87 | 41.74 |
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.